News
Making the Most of Health Data to Deliver Pharmaceutical Innovation: What Are the Legal Barriers?
20 December 2018
OHE publishes a report on the legal barriers to the better use of health data to deliver pharmaceutical innovation.
“You Don’t Always Get What You Want”: Output Distortion and NHS Waiting Time Targets
18 December 2018
The latest publication from Professor Graham Cookson in Public Organization Review finds that waiting time targets adopted in the English NHS as part of the ‘targets…
A Note on the Relationship Between Age and Health-related Quality of Life Assessment
12 December 2018
A new OHE-authored paper on the relationship between age and health-related quality of life has been published in Quality of Life Research.
New Publications: Real-World Evidence for Coverage and Formulary Decisions
7 December 2018
Two articles, published in the Journal of Comparative Effectiveness Research, explore the use of real-world evidence for coverage and formulary decisions.
New NICE Position Statement – 5L Value Set Still ‘On Hold’
29 November 2018
NICE has issued a new position statement regarding the use of the EQ-5D-5L value set in evidence submitted to its HTA process.
EQ-5D-5L Value Set for England Study Team Responds to the EEPRU Review
29 November 2018
OHE has published a response to the critique of the EQ-5D-5L value set for England study.
Approaches, Challenges and Successful Stories of Multi-indication Pricing in Europe
28 November 2018
Multi-Indication Pricing: Practical Solutions and Steps to Move Forward. A summary of an HTAi panel session.
Presentations from ISPOR Europe 2018
23 November 2018
OHE staff recently attended the ISPOR Europe conference in Barcelona. In this blog post, we share a selection of our presentations.
OHE Lunchtime Seminar: Price Regulation of Generics and Drug Shortages
21 November 2018
OHE Lunchtime Seminar with Dr. Aslam Anis, The University of British Columbia. The seminar will discuss the impact of the pan-Canadian Pharmaceutical Alliance “tiered pricing” framework…